Publicaciones en colaboración con investigadores/as de University of Queensland (18)

2020

  1. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens

    Scientific Reports, Vol. 10, Núm. 1

  2. Temperate Bacteriophages (Prophages) in Pseudomonas aeruginosa Isolates Belonging to the International Cystic Fibrosis Clone (CC274)

    Frontiers in Microbiology, Vol. 11

2019

  1. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

    Clinical Infectious Diseases, Vol. 69, Núm. 10, pp. 1812-1816

2018

  1. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance

    Intensive Care Medicine

  2. Defining antimicrobial resistance in cystic fibrosis

    Journal of Cystic Fibrosis, Vol. 17, Núm. 6, pp. 696-704

  3. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

    Clinical Microbiology and Infection, Vol. 24, pp. e1-e38

2017

  1. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

    The Lancet Infectious Diseases, Vol. 17, Núm. 7, pp. 726-734

  2. Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone

    Scientific Reports, Vol. 7, Núm. 1

  3. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study

    International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672

2016

  1. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae

    Mayo Clinic Proceedings, Vol. 91, Núm. 10, pp. 1362-1371

  2. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169

  3. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 6, pp. 1672-1680

  4. Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: The Bacteraemia-MIC project

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 2, pp. 521-530

2014

  1. General statistical framework for quantitative proteomics by stable isotope labeling

    Journal of Proteome Research, Vol. 13, Núm. 3, pp. 1234-1247

2013

  1. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010

    International Journal of Antimicrobial Agents, Vol. 41, Núm. 3, pp. 224-228

2009

  1. Redefining extended-spectrum β-lactamases: Balancing science and clinical need

    Journal of Antimicrobial Chemotherapy

  2. Redefining extended-spectrum β-lactamases: Balancing science and clinical need-authors' response

    Journal of Antimicrobial Chemotherapy

2002

  1. Further molecular discrimination of Spanish strains of Echinococcus granulosus

    Experimental Parasitology, Vol. 102, Núm. 1, pp. 46-56